There is an increasing need in routine clinical neuroimaging for simple and accessible methodologies which can reduce examination times but still provide reliable information about the status of the disease. More widespread use of PET technology would be favoured by avoiding the investment and running expenses associated with an onsite cyclotron. The clinical implementation of PET would benefit from cost reductions. The use of isotope generators could potentially allow centres remote from a cyclotron to have access to a wide range of radiopharmaceuticals.
The zinc-62/copper-62 ( 62 Zn/ 62 Cu) generator is a closeto-optimal radionuclide source for labelling chemically diverse ligands. 62 Zn is produced by the nuclear reaction 63 Cu(p,n) 62 Zn with a proton beam of 27.5 MeV, fitting well with on-demand production by a regional medium-energy cyclotron [1] [2] [3] . The generator is compact, is easy to produce and ship and is relatively inexpensive, and the eluate is either automatically chelated by thiosemicarbazone complexes (i.e. ATSM and PTSM) [4] or mixed manually [5] . The 9.3-h half-life of 62 Zn limits the use of the generator to a single day, during which up to 20 doses can be produced. Conversely, the 9.7-min half-life of 62 Cu is short enough to offer the opportunity in a single patient to perform sequential studies as well as studies involving dual tracer combinations in which a 62 Cu investigation can be combined with, for example, an 18 F labelled radiopharmaceutical to provide complementary information [5, 6] .
The almost exclusive β + emission (97%) of 62 Cu impacts positively on the true coincidences and hence on the sensitivity and count rate, giving good counting statistics even for less-sensitive PET cameras. The short physical halflife of 62 Cu and the biodistribution patterns of its thiosemicarbazone complexes result in effective doses (0.36 mSv/ 100 MBq) of the same order as 15 O-water (0.1 mSv/ 100 MBq), which is in the lower range of the most used radiopharmaceuticals (i.e. 18 F-FDG, 1.9 mSv/100 MBq) [7] . On the other hand, the high positron energy of Cu to precisely detect changes in small areas. In this issue of the European Journal of Nuclear Medicine and Molecular Imaging Isozaki et al. [8] report a wellconducted study with highly accurate assessments of haemodynamic status using a minimally invasive and time-effective methodology. They used for the first time in cerebrovascular disease 62 Cu-ATSM, a radiopharmaceutical originally developed for probing hypoxic tissue [9] and recently proven to be effective in imaging tumours [5] and acute stroke [6] . They were able to demonstrate a highly significant relationship between the early phase (first 3 min after injection) uptake of 62 Cu-ATSM and cerebral blood flow images as evaluated by a bolus injection of 15 O-water. Moreover, the ratio between its late phase (last 10 min after injection) and the early phase was significantly correlated with the oxygen extraction fraction as measured by a bolus inhalation of 15 O 2 . The conclusion was that dynamic PET acquisition with 62 Cu-ATSM provides information about the haemodynamic status of patients with chronic cerebrovascular disease equivalent to that obtained by 15 [10] . Furthermore, the need for repeated manual arterial sampling requires arterial lines and the mandatory presence of an operator beside the bed resulting in a high stress level for the patient. The proposed non-invasive imaging method by a single intravenous injection of 62 Cu-ATSM provided, in a 20-min examination time, information about both regional cerebral blood flow and hypoxic changes due to ischaemia. This information is extremely relevant in the evaluation of cerebrovascular disease, helping to identify the tissue suffering from chronic misery perfusion which can possibly be saved by neurosurgical treatment.
Cu-ATSM has shown a selective hypoxia-related retention [9, [11] [12] [13] [14] [15] [16] [17] . It is highly lipophilic and shows quick penetration through the blood-brain barrier as well as through cell and mitochondrial membranes [18, 19] . Under hypoxic conditions impairment of the electron transport system of mitochondria favours the reduction of Cu-ATSM at the complex I site using NADH as an electron donor [9] . Cu(II)-ATSM reduction probably occurs in all cells and results in an unstable Cu(I)-ATSM, which in turn, in the presence of oxygen, can be oxidized back to Cu(II)-ATSM and freely diffuse in and out of the cell [20, 21] . In a hypoxic cellular environment Cu(I)-ATSM will slowly and irreversibly dissociate, becoming trapped in the cell and absorbed by the intracellular Cu pool [9] . The key factors accounting for Cu-ATSM accumulation are probably the high NADH-NADPH concentration and a decrease in intracellular pH from the over-reduced hypoxic tissue [16] . However, the reductive retention of Cu-ATSM requires intact mitochondria and its accumulation is associated with cell viability (for review see reference [22] ).
These biochemical characteristics of Cu-ATSM agents have been previously exploited in studies of tumours in which the definition of the hypoxic regions surrounding the necrotic core is of the utmost importance in the planning of radio-and chemotherapy (for review see reference [14] ). Studies have shown that Cu-ATSM distributes mainly in the outer still-viable rim of tumour masses while 18 F-FDG accumulates in the inner prenecrotic regions [5, 23, 24] . Cu-ATSM agents have also been compared to other hypoxic agents such as 2-nitroimidazoles ( 18 F-FMISO) with concordant findings in early and late images (16-20 h after injection using 64 Cu) [25] . The particular clinical usefulness of In addition to cerebrovascular disease [8] and MELAS [6] , 62 Cu-ATSM could be of use in targeting viable hypoxic tissue with high specificity for planning radiotherapy of brain tumours, in psychiatric studies in which mitochondrial damage is suspected to be a contributing factor, and in neuropsychiatry to elucidate the role of hypoxia in Alzheimer's and Parkinson's diseases. All of these potential advantages of 62 Cu-ATSM should be carefully taken into account by members of the European community of nuclear medicine for considering the possibility of also producing 
